

# Supporting Information

## Machine learning-based virtual screening for the identification of Cdk5 inhibitors

*Miriana Di Stefano<sup>a,b</sup>, Salvatore Galati<sup>a</sup>, Gabriella Ortore<sup>a</sup>, Isabella Caligiuri<sup>c</sup>, Flavio Rizzolio<sup>c,d</sup>,  
Costanza Ceni<sup>a,b</sup>, Simone Bertini<sup>a</sup>, Giulia Bononi<sup>a</sup>, Carlotta Granchi<sup>a</sup>, Marco Macchia<sup>a</sup>, Giulio Poli<sup>a,\*</sup>,  
Tiziano Tuccinardi<sup>a</sup>*

<sup>a</sup> Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.

<sup>b</sup> Department of Life Sciences, University of Siena, Via Aldo Moro, 2, 53100 Siena, Italy.

<sup>c</sup> Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.

<sup>d</sup> Department of Molecular Sciences and Nanosystems, Ca' Foscari University, 30123 Venezia, Italy.

### Table of Contents

<b>Table S1.</b> Cross validation results obtained for RF-based models.	S2
<b>Table S2.</b> Cross validation results obtained for KNN-based models.	S2
<b>Table S3.</b> Cross validation results obtained for SVM-based models.	S3
<b>Table S4.</b> Cross validation results obtained for MLP-based models.	S3
<b>Table S5.</b> Hyperparameters setup of the best performing model, used for virtual screening.	S4
<b>Figure S1.</b> CDK5 IC <sub>50</sub> plots for compounds CPD1 and CPD4.	S4

**Table S1.** Evaluation results, expressed in terms of MCC, obtained for RF-based models developed through cross-validation analysis.

Fingerprint	MCC
Morgan	$0.65 \pm 0.05$
Layer	$0.63 \pm 0.05$
Pattern	$0.62 \pm 0.06$
Pharm2D	$0.60 \pm 0.05$
RDKit	$0.59 \pm 0.05$
MACCS	$0.54 \pm 0.05$

**Table S2.** Evaluation results, expressed in terms of MCC, obtained for KNN-based models developed through cross-validation analysis.

Fingerprint	MCC
Morgan	$0.60 \pm 0.04$
RDKit	$0.59 \pm 0.05$
Layer	$0.59 \pm 0.03$
Pharm2D	$0.54 \pm 0.06$
Pattern	$0.53 \pm 0.05$
MACCS	$0.50 \pm 0.06$

**Table S3.** Evaluation results, expressed in terms of MCC, obtained for SVM-based models developed through cross-validation analysis.


Fingerprint	MCC
Morgan	$0.69 \pm 0.04$
Pattern	$0.63 \pm 0.05$
RDKit	$0.60 \pm 0.08$
Pharm2D	$0.60 \pm 0.03$
Layer	$0.59 \pm 0.07$
MACCS	$0.55 \pm 0.07$

**Table S4.** Evaluation results, expressed in terms of MCC, obtained for MLP-based models developed through cross-validation analysis.

Fingerprint	MCC
Morgan	$0.67 \pm 0.08$
Pattern	$0.59 \pm 0.05$
RDKit	$0.58 \pm 0.11$
Pharm2D	$0.58 \pm 0.05$
Layer	$0.53 \pm 0.05$
MACCS	$0.47 \pm 0.06$

**Table S5.** Hyperparameters setup of the best performing model, used for virtual screening.

Hyperparameter	Value
Max_features	log2
n_estimators	500
Class_weight	None
Min_samples_split	2
Min_samples_leaf	1
Max_depth	None



**Figure S1.** CDK5 IC<sub>50</sub> plots for compounds **CPD1** (left side) and **CPD4** (right side).